Build the Plan for a Milestone-Priced Market

Boston Scientific paid $1.5 billion on May 18 for a 34% equity stake in MiRus, with an option to acquire the rest of the TAVR business for an additional $3 billion in milestone-gated payments tied to the SIEGEL valve’s clinical and regulatory progress. Stryker closed $835 million for Amplitude Vascular on May 7, with roughly half in milestones. Embecta closed £150 million for Owen Mumford on May 15, with a third in milestones. HistoSonics submitted a De Novo on May 11 for kidney tumor expansion of an existing Edison Histotripsy platform authorization. The CMS-FDA RAPID Coverage Pathway, operationalized this quarter, compresses Medicare coverage to 60 to 90 days after FDA marketing authorization against a prior baseline that often ran past six months. The MedTech commercialization environment is pricing milestones rather than finished assets, and founders who finish in regulated hardware design the operating plan against that pricing logic from initial company architecture.

If You Are Building a Company in This Environment

The default first-time medical device, diagnostics, defense-hardware, or industrial-robotics founder treats the path to commercial scale as a single discrete moment, with a single exit-price assumption modeled at the seed stage and held constant against whatever the buyer side actually offers when the term sheet arrives. The build-phase logic is that the technical capability is the asset the strategic acquirer will buy, that the regulatory pathway is the gate the agency will price the asset against, and that the reimbursement question is the function the company will resolve at commercial launch. The four signals across the past two weeks reframe the logic. Boston Scientific paying $1.5 billion for 34% of MiRus with a $3 billion milestone-gated option tells you the acquirer is pricing the milestones, not the asset. Stryker’s $835 million Amplitude close and Embecta’s £150 million Owen Mumford close confirm the structure is the operating posture across the buyer side, not a one-off term. HistoSonics’s second-indication De Novo submission shows how platform-milestone sequencing becomes the unit of value across multiple readouts. The RAPID Coverage Pathway compresses the reimbursement timeline to a single FDA-CMS milestone window the operating plan can finally price with materially less timeline uncertainty than the prior decade allowed.

Founders who finish in regulated hardware run the milestone schedule as the operating cash-flow schedule of the business. They sequence the next four to six fundable clinical, regulatory, and commercial milestones across the operating horizon, price each one against the cash flow and the financing event it anchors, design the technical and clinical evidence base so each milestone is verifiable to an external auditor, build the post-market quality and reimbursement architecture for the joint FDA-CMS milestone window the RAPID pathway just created, and update the milestone schedule on a quarterly review rhythm against the most recent agency and buyer-side signal. They resource the milestone operating system as a Day-1 capital line that compounds across the build phase into the participation profile the strategic acquirer, the payer, and the investor pricing the round all read at the moment the deal conversation begins.

The version of the deal-structure decision that breaks first-time hard-tech founders is the one that begins at the term-sheet table. The founder discovers the milestone-gated structure when the buyer pulls the milestone schedule, the founder operating plan does not have a corresponding milestone schedule that prices each one against the cash flow and financing event, and the post-deal value migrates to the buyer’s milestone-pricing logic rather than to the founder’s single-exit assumption. The cost shows up at the moment the operating plan needed the headline number to be the realized number, and the deal closes against a structure the founder did not architect the business to optimize for.

What the Four Signals Tell You About the Operating Plan You Need

The four signals across May 2026 describe what the operating plan inside a finishing medical device, diagnostics, defense-hardware, climate-hardware, or platform-tech business actually has to deliver. Boston Scientific tells you the strategic acquirer will gate 30 to 50 percent of headline value behind clinical and regulatory milestones the term sheet enumerates. Stryker and Embecta confirm the structure is the operating posture across the buyer side, not a one-off term applied to an unusual asset. HistoSonics shows that a platform technology with a credible evidence base sequences into a multi-indication asset, where each new indication is a fundable milestone the operating plan stages against. RAPID confirms the payer side is pricing the same milestones, with the proposed coverage determination issued the same day as FDA marketing authorization and the final determination 60 to 90 days later.

The architectural work that separates the regulated-hardware companies that finish from the ones that stall in this environment is the operating plan that runs against milestone-priced cash flow rather than against a single-exit assumption. The companies that finish design the milestone schedule as the operating cadence, run the technical and clinical evidence base to make each milestone legible to external auditors, build the post-market quality and reimbursement architecture for the joint FDA-CMS window the RAPID pathway just created, and update the milestone schedule on a quarterly review rhythm. The companies that stall build the seed-stage operating model around a single exit number, model the path to that number against a static set of regulatory and commercial assumptions, and discover at the term sheet table or the launch window that the buyer and payer side are pricing something else.

What Milestone Operating Discipline Looks Like at Scale

The companies that win on milestone operating discipline do specific architectural and operating work that is easy to defer and expensive to skip. They sequence the clinical, regulatory, and commercial milestones the business will hit over a four-to-eight quarter horizon and price each one against the cash flow and financing event it anchors. They design the technical and clinical evidence base to make each milestone verifiable to an external party, with the supporting documentation built from the start rather than retrofitted at deal time. They build the post-market quality and reimbursement architecture for the joint FDA-CMS milestone window the RAPID pathway just created, with the financing, the inventory build, and the commercial team sized against the joint event rather than against two separate inflection points. They run the supplier-customer quality system to absorb the cascade exposure the current environment is producing, with supplier-side quality agreements and downstream notification cadences that absorb a recall without rewiring the gross margin trajectory.

At the operating level, the discipline shows up as a quarterly milestone review that runs alongside the engineering, clinical, and commercial cadence with the same operating intensity. The review covers the next four to six fundable milestones against the operating plan, the cash flow and financing event each milestone anchors, the regulatory and reimbursement timeline against the most recent agency signal, the supplier-customer post-market exposure, and the participation profile the buyer and payer side read at the moment the deal conversation begins. Founders who run that quarterly review can absorb a term-sheet conversation, a financing window, or a strategic acquisition without rewiring the operating plan. Founders who do not run it cannot, and the cost of the missing review arrives at every commercial and capital window between now and the exit.

The Five Questions for the Milestone Operating Decision

The five-question framework in Founders Who Finish reframes what a credible operating plan actually requires the team to deliver in a regulated-hardware environment where the strategic acquirer is gating 30 to 50 percent of headline value behind clinical and regulatory milestones, the payer side has collapsed FDA authorization and Medicare coverage into a single milestone window, and platform companies are sequencing indications as the unit of fundable value.